Company intelligence / Profile preview

Resilient Biotics

Durham, North Carolina, United Statesresilientbiotics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Resilient Biotics develops live biotherapeutic products using proprietary microbiome analytics to prevent or treat complex respiratory infections. Their approach aims to reduce antibiotic dependency by leveraging commensal microorganisms as a barrier against pathogens. The company has secured venture funding and strategic partnerships, with ongoing preclinical/early clinical testing in both human and animal health applications.

Therapeutic areas: Infectious Diseases
Modalities: live biotherapeuticsmicrobiome-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

RBX001

Preclinical

Partnerships

At least one strategic partnership has been secured to enable development of novel respiratory microbiome products (partner(s) not named).

Beyond the preview

Go deeper on Resilient Biotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resilient Biotics.

Explore the full profile